Total Payments
$270,789
2024 Payments
$24,841
Companies
22
Transactions
268
Medicare Patients
275
Medicare Billing
$33,064
Payment Breakdown by Category
Consulting$161,488 (59.6%)
Other$41,068 (15.2%)
Travel$27,589 (10.2%)
Research$27,123 (10.0%)
Education$6,894 (2.5%)
Food & Beverage$6,627 (2.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $161,488 | 47 | 59.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $29,288 | 20 | 10.8% |
| Travel and Lodging | $27,589 | 60 | 10.2% |
| Unspecified | $27,123 | 33 | 10.0% |
| Honoraria | $11,780 | 2 | 4.4% |
| Education | $6,894 | 11 | 2.5% |
| Food and Beverage | $6,627 | 95 | 2.4% |
Payments by Type
General
$243,666
235 transactions
Research
$27,123
33 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $49,530 | 43 | $0 (2024) |
| Genentech USA, Inc. | $33,769 | 19 | $0 (2022) |
| EMD Serono, Inc. | $32,415 | 36 | $0 (2022) |
| Genentech, Inc. | $24,798 | 22 | $0 (2024) |
| F. Hoffmann-La Roche AG | $24,336 | 29 | $0 (2024) |
| Biogen, Inc. | $24,328 | 35 | $0 (2024) |
| Celgene Corporation | $19,296 | 22 | $0 (2024) |
| Horizon Therapeutics plc | $13,304 | 11 | $0 (2022) |
| E.R. Squibb & Sons, L.L.C. | $9,791 | 13 | $0 (2024) |
| Merck KGaA | $9,175 | 4 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $24,841 | 16 | Novartis Pharmaceuticals Corporation ($7,182) |
| 2023 | $10,346 | 11 | GENZYME CORPORATION ($2,695) |
| 2022 | $41,541 | 41 | EMD Serono, Inc. ($11,989) |
| 2021 | $28,958 | 18 | Horizon Therapeutics plc ($9,812) |
| 2020 | $24,999 | 27 | F. Hoffmann-La Roche AG ($5,752) |
| 2019 | $59,153 | 54 | Genentech USA, Inc. ($17,073) |
| 2018 | $35,226 | 38 | Genentech, Inc. ($11,929) |
| 2017 | $45,724 | 63 | Biogen, Inc. ($14,528) |
All Payment Transactions
268 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/12/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,560.00 | General |
| 10/22/2024 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $2,800.00 | General |
| 10/11/2024 | Genentech, Inc. | Ocrevus (Biological) | Consulting Fee | Cash or cash equivalent | $5,513.99 | General |
| Category: Immunology | ||||||
| 10/11/2024 | Genentech, Inc. | Ocrevus (Biological) | Education | In-kind items and services | $747.12 | General |
| Category: Immunology | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $1,983.60 | Research |
| Study: MNT OBOE • Category: Immunology | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $1,478.00 | Research |
| Study: MNT OBOE • Category: Immunology | ||||||
| 09/19/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $133.29 | General |
| Category: Neurology | ||||||
| 09/18/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $78.42 | General |
| 05/29/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $135.89 | General |
| Category: Neurology | ||||||
| 05/09/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Education | In-kind items and services | $100.00 | General |
| Category: Rare Disease | ||||||
| 03/22/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Consulting Fee | Cash or cash equivalent | $5,575.00 | General |
| Category: Neurology | ||||||
| 03/22/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Travel and Lodging | In-kind items and services | $291.38 | General |
| Category: Neurology | ||||||
| 03/22/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $200.97 | General |
| Category: Neurology | ||||||
| 03/21/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Travel and Lodging | In-kind items and services | $705.96 | General |
| Category: Neurology | ||||||
| 03/21/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $140.00 | General |
| Category: Neurology | ||||||
| 02/08/2024 | Biogen, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,397.50 | General |
| 12/31/2023 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $1,055.80 | Research |
| Study: Reduction of intrathecal immunoglobulin levels with ocrelizumab treatment in relapsing and primary progressive multiple sclerosis • Category: Immunology | ||||||
| 12/18/2023 | GENZYME CORPORATION | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,572.50 | General |
| 10/11/2023 | Genentech, Inc. | Ocrevus (Biological) | Food and Beverage | In-kind items and services | $41.46 | General |
| Category: Immunology | ||||||
| 08/29/2023 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $122.78 | General |
| 07/11/2023 | Biogen, Inc. | TYSABRI (Biological) | Consulting Fee | Cash or cash equivalent | $150.00 | General |
| Category: Neurology | ||||||
| 06/30/2023 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $799.08 | Research |
| Study: Demographics and Baseline Disease Characteristics of Black and Hispanic Patients With Multiple Sclerosis in the Open-Label, Single-Arm, Multicenter, Phase IV CHIMES Trial • Category: Immunology | ||||||
| 06/13/2023 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,480.00 | General |
| 06/01/2023 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $79.20 | General |
| Category: Neurology | ||||||
| 03/08/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $93.58 | General |
| Category: Neuroscience | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $5,041 | 4 |
| AN OPEN-LABEL, MULTICENTER, BIOMARKER STUDY TO EXPLORE THE MECHANISM OF ACTION OF OCRELIZUMAB AND B-CELL BIOLOGY IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS OR PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS | F. Hoffmann-La Roche AG | $4,913 | 10 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH ARZERRA RESEARCH | Novartis Pharmaceuticals Corporation | $4,006 | 1 |
| Publication support research related | Novartis Pharma AG | $3,803 | 2 |
| MNT OBOE | F. Hoffmann-La Roche AG | $3,462 | 2 |
| Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS) | Biogen, Inc. | $2,155 | 9 |
| Reduction of intrathecal immunoglobulin levels with ocrelizumab treatment in relapsing and primary progressive multiple sclerosis | F. Hoffmann-La Roche AG | $1,056 | 1 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Active-Reference (Ocrelizumab), Parallel-Group, Dose-Ranging Phase 2 Study to Evaluate the Efficacy and Safety of Intravenous Dapirolizumab Pegol (BIIB133) in Relapsing Multiple Sclerosis. | Biogen, Inc. | $1,050 | 1 |
| AN OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB IN PATIENTS WITH EARLY STAGE RELAPSING REMITTING MULTIPLE SCLEROSIS | F. Hoffmann-La Roche AG | $838.24 | 2 |
| Demographics and Baseline Disease Characteristics of Black and Hispanic Patients With Multiple Sclerosis in the Open-Label, Single-Arm, Multicenter, Phase IV CHIMES Trial | F. Hoffmann-La Roche AG | $799.08 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 94 | 129 | $41,809 | $11,466 |
| 2022 | 2 | 62 | 92 | $26,799 | $7,103 |
| 2021 | 4 | 80 | 100 | $38,063 | $10,831 |
| 2020 | 1 | 39 | 42 | $18,270 | $3,664 |
Total Patients
275
Total Services
363
Medicare Billing
$33,064
Procedure Codes
10
All Medicare Procedures & Services
10 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 50 | 63 | $27,405 | $8,022 | 29.3% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 23 | 23 | $9,545 | $2,375 | 24.9% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 21 | 43 | $4,859 | $1,069 | 22.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 39 | 53 | $23,055 | $6,253 | 27.1% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2022 | 23 | 39 | $3,744 | $850.64 | 22.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 41 | 51 | $22,185 | $6,648 | 30.0% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 13 | 13 | $7,956 | $2,086 | 26.2% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 14 | 14 | $5,810 | $1,526 | 26.3% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2021 | 12 | 22 | $2,112 | $571.43 | 27.1% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 39 | 42 | $18,270 | $3,664 | 20.1% |
About Dr. Anne Cross, MD
Dr. Anne Cross, MD is a Neurology healthcare provider based in Saint Louis, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1073531596.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Anne Cross, MD has received a total of $270,789 in payments from pharmaceutical and medical device companies, with $24,841 received in 2024. These payments were reported across 268 transactions from 22 companies. The most common payment nature is "Consulting Fee" ($161,488).
As a Medicare-enrolled provider, Cross has provided services to 275 Medicare beneficiaries, totaling 363 services with total Medicare billing of $33,064. Data is available for 4 years (2020–2023), covering 10 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Saint Louis, MO
- Active Since 07/17/2006
- Last Updated 04/17/2025
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1073531596
Products in Payments
- OCREVUS (Biological) $66,696
- GILENYA (Drug) $22,346
- Ocrevus (Biological) $17,371
- KESIMPTA (Drug) $14,525
- UPLIZNA (Drug) $13,304
- ARZERRA (Drug) $12,850
- Mavenclad (Biological) $11,906
- Ozanimod (Drug) $8,701
- TYSABRI (Biological) $8,399
- Betaseron (Drug) $6,722
- ZEPOSIA (Drug) $2,093
- Ponvory (Drug) $1,320
- Mavenclad (Drug) $1,111
- VUMERITY (Drug) $1,050
- OMB157G_ARZERRA_HEMATOLOGY (Drug) $846.64
- LEMTRADA (Drug) $121.64
- ULTOMIRIS (Biological) $100.00
- OMB157G (Drug) $96.65
- MAYZENT (Drug) $84.27
- AUBAGIO (Drug) $79.74
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Saint Louis
Barry Singer
Neurology — Payments: $2.7M
Neurology $2.7M
Dr. Mark Tullman, M.d, M.D
Neurology — Payments: $2.1M
Neurology $2.1M
Dr. Robert Naismith, Md, MD
Neurology — Payments: $774,163
Neurology $774,163
Dr. Barbara Green, Md, MD
Neurology — Payments: $597,464
Neurology $597,464
Dr. Arun Varadhachary, Md, MD
Neurology — Payments: $373,665
Neurology $373,665
Pratap Chand, Md, MD
Neurology — Payments: $210,058
Neurology $210,058